Thanks for your thoughts as well. I agree it's under valued, I just worry it may take a while for the value to catch up as they've got to make the numbers work better first before we see it pop.
Galliprant works just like other NSAIDS it just targets what we want to hit more specifically so less long term sides and it can be used on patients with some conditions that keep us from using other NSAIDS. If Elanco can get the price down close to what Rimadyl is then I think it will start moving off the shelves a lot quicker. There are generics of Rimadyl now for half the price and that's what a lot of clinics use so when you compare generic Carprofen to Galliprant it's a HUGE price difference per month. Once that gap closes the sales will pick up for Galliprant without a doubt
News 
Market Data 
Discover 
